glp-1 candidates Market Overview: Agonists and the Obesity Market | Blog How GLP-1 Receptor Agonists Evolved

The material sold as research semaglutide in multi-dose vials for reconstitution is not an approved product, is not sterility-tested for human use, and is sold strictly for laboratory research

A study published in the New England Journal of Medicine this month found Zepbound outperformed Wegovy in a head-to-head clinical trial

recovery is unpredictable, and there is no guaranteed way to reverse it once optic nerve tissue is damaged

Research from the STEP trials, which studied semaglutide 2.4mg weekly, found that approximately 75% of the weight lost was fat mass rather than lean mass

A 2024 study from Beth Israel Deaconess Medical Center found that about 15 million Americans use the new generation of weight-loss drugs, known as GLP-1 agonists, which require a once-weekly injection